OCULOcular Therapeutix, Inc.
Price
-38%1YEnd-of-day closes, not the intraday tick.
The checks lean against it
Quality shaky, a flag to check, growth fading, the market against it.
We are an integrated biopharmaceutical company committed to redefining the retina experience. AXPAXLI, also known as OTX-TKI, our investigational product candidate for retinal disease, is an axitinib intravitreal hydrogel based on our ELUTYX proprietary bioresorbable hydrogel-based formulation technology. AXPAXLI is currently being evaluated in a Phase 3 registrational program for wet age-related macular degeneration, or wet AMD, which we refer to as the SOL program.
In the company’s own words · 10-K filed Feb 5, 2026 · SEC EDGAR
Charts
As reported to the SEC, without any scoring.
Ocular Therapeutix, Inc. (OCUL) reported revenue of $13M in Q2 2026 (quarter ended Jun 30, 2026), up 0.1% from the same quarter a year earlier. That came with a gross margin of 85% and net loss of $79M. For the full year FY2025, revenue was $52M (−18% year on year) and net income −$266M. Its largest product in Q3 2024 (quarter ended Sep 30, 2024) was Collaboration at $78K, 50.0% of the disclosed total, just ahead of Otx Tic Product at 50.0%. The next results filing is expected around Nov 3, 2026, the same week as a year ago.
What the company said
The company's own words from its current reports to the SEC, newest first
- Aug 3, 2026Reports Second Quarter 2026 Financial Results and Business Highlights.Earnings release · press release
- Jun 12, 2026Amendment to 2021 Stock Incentive Plan On June 10, 2026, Ocular Therapeutix, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “2026 Annual Meeting”)Director or officer change · Form 8-K
- May 5, 2026Ocular Therapeutix™ Reports First Quarter.Earnings release · press release
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Business segments
Q3 2024 · $156.0KThe company’s own SEC segment disclosure.
- Collaboration$78.0K50%
- Otx Tic Product$78.0K50%
Why these answers
Each answer with the checks it was read from. Open one for the numbers.
Conflicts between checks are named, never averaged, and thin data says so.